Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI - PACE-CME

Possible substitution of aspirin by PY inhibitor monotherapy one year after PCI

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

A call to solve the controversy on omega-3FAs trials
A call to solve the controversy on omega-3FAs trials
ACC.21
A call to solve the controversy on omega-3FAs trials
- Prof. Eileen Handberg, PhD
No superiority with NOAC compared to standard care following TAVI
No superiority with NOAC compared to standard care following TAVI
ACC.21
No superiority with NOAC compared to standard care following TAVI
- Jean-Philippe Collet, MD, PhD
12-Months follow up of rapid hs -TnT protocol in ACS suspected patients
12-Months follow up of rapid hs -TnT protocol in ACS suspected patients
ACC.21
12-Months follow up of rapid hs -TnT protocol in ACS suspected patients
- Prof. Derek Chew
No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD
No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD
ACC.21
No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD
- William Schuyler Jones, MD